FDAnews Drug Daily Bulletin

MANHATTAN PHARMACEUTICALS DOSES FIRST PATIENT GROUP IN PHASE IIA TRIAL FOR OE, ITS ORAL OBESITY DRUG CANDIDATE

June 30, 2006
A A

Manhattan Pharmaceuticals, Inc. today announced that it commenced dosing the first group of patients in its Phase IIa clinical trial of oral Oleoyl-estrone (OE), the company's novel drug candidate for the treatment of obesity. Patient recruitment is ongoing. Yahoo News (http://biz.yahoo.com/prnews/060629/nyth096.html?.v=61)